CA2321191A1 - Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 - Google Patents
Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 Download PDFInfo
- Publication number
- CA2321191A1 CA2321191A1 CA002321191A CA2321191A CA2321191A1 CA 2321191 A1 CA2321191 A1 CA 2321191A1 CA 002321191 A CA002321191 A CA 002321191A CA 2321191 A CA2321191 A CA 2321191A CA 2321191 A1 CA2321191 A1 CA 2321191A1
- Authority
- CA
- Canada
- Prior art keywords
- ligand
- substituted
- linker
- ligands
- linkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZNRGQMMCGHDTEI-UHFFFAOYSA-N CN(C(CC1)C2)C1CC2OC(c1c[nH]c2ccccc12)=O Chemical compound CN(C(CC1)C2)C1CC2OC(c1c[nH]c2ccccc12)=O ZNRGQMMCGHDTEI-UHFFFAOYSA-N 0.000 description 1
- VQFNBXKTCGXRAS-UHFFFAOYSA-N C[n]1nc(C(NCC2CC(CCC3)N(C)C3C2)=O)c2ccccc12 Chemical compound C[n]1nc(C(NCC2CC(CCC3)N(C)C3C2)=O)c2ccccc12 VQFNBXKTCGXRAS-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1ncc[n]1CC(CCc1c2c3ccccc3[n]1)C2=* Chemical compound Cc1ncc[n]1CC(CCc1c2c3ccccc3[n]1)C2=* 0.000 description 1
- KZLSHTHSLXQCSZ-UHFFFAOYSA-N NC(C(CC(C1)C2)CC1CC2OC(c1c[nH]c2c1cccc2)=O)=O Chemical compound NC(C(CC(C1)C2)CC1CC2OC(c1c[nH]c2c1cccc2)=O)=O KZLSHTHSLXQCSZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés ou agents à plusieurs liaisons et qui se lient aux récepteurs 5-HT¿3?. Ces composés comportent une pluralité de ligands dont chacun peut se lier à de tels récepteurs, modulant ainsi les fonctions ou processus biologiques de ces récepteurs. Chacun des ligands est attaché par covalence à un lieur ou à des lieurs qui peuvent être identiques ou différents, et ce, de façon à constituer un composé capable de liaisons multiples. Le choix du lieur est fait pour que le composé à liaisons multiples fasse preuve d'une modulation accrue des processus biologiques à médiation du récepteur 5-HT¿3?.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8846698P | 1998-06-08 | 1998-06-08 | |
US60/088,466 | 1998-06-08 | ||
US9293898P | 1998-07-15 | 1998-07-15 | |
US60/092,938 | 1998-07-15 | ||
US12028299P | 1999-02-16 | 1999-02-16 | |
US60/120,282 | 1999-02-16 | ||
PCT/US1999/012768 WO1999064046A1 (fr) | 1998-06-08 | 1999-06-08 | Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3? |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2321191A1 true CA2321191A1 (fr) | 1999-12-16 |
Family
ID=27375973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002321191A Abandoned CA2321191A1 (fr) | 1998-06-08 | 1999-06-08 | Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1085888A1 (fr) |
AU (1) | AU4551499A (fr) |
CA (1) | CA2321191A1 (fr) |
WO (1) | WO1999064046A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003100091A1 (fr) * | 2002-05-24 | 2003-12-04 | Epidauros Biotechnologie Ag | Moyens et methodes de traitement ameliores utilisant des 'setrones' |
GB2398071B (en) * | 2003-01-24 | 2006-06-07 | Synthon Bv | Process for making ondansetron and intermediate thereof |
TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510132B1 (fr) * | 1990-09-28 | 1997-05-14 | Neorx Corporation | Porteurs polymeres servant a la liberation d'agents a liaison covalente |
WO1997035195A1 (fr) * | 1996-03-19 | 1997-09-25 | The Salk Institute For Biological Studies | Procede d'identification in vitro de modulateurs de membres de la superfamille des recepteurs des steroides ou thyroides |
-
1999
- 1999-06-08 WO PCT/US1999/012768 patent/WO1999064046A1/fr not_active Application Discontinuation
- 1999-06-08 AU AU45514/99A patent/AU4551499A/en not_active Abandoned
- 1999-06-08 CA CA002321191A patent/CA2321191A1/fr not_active Abandoned
- 1999-06-08 EP EP99928450A patent/EP1085888A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1085888A1 (fr) | 2001-03-28 |
WO1999064046A1 (fr) | 1999-12-16 |
WO1999064046A9 (fr) | 2000-04-20 |
AU4551499A (en) | 1999-12-30 |
WO1999064046A8 (fr) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6355805B1 (en) | β3-adrenergic receptor agonists | |
US6693202B1 (en) | Muscarinic receptor antagonists | |
CA2319495A1 (fr) | Inhibiteurs multiliaison de proteine triglyceride transferase microsomique | |
WO1999064043A9 (fr) | Antagonistes des recepteurs muscariniques | |
US6420560B1 (en) | H1—histamine receptor antagonists | |
WO1999064039A9 (fr) | Antagonistes de bradykinine | |
CA2321191A1 (fr) | Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 | |
ZA200004083B (en) | H1-histamine receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |